# Studies of composition, weight and function

> Reading list: TX Medical Weight Loss Center — The TX Medical Weight Loss Center reading list: tirzepatide body composition and withdrawal, semaglutide weight and heart studies, and tolerability.

**Reading list**

The body-composition finding starts the argument. These other results give it scale, duration and complications.

## Composition studies

The [SURMOUNT-1 DXA substudy](https://pubmed.ncbi.nlm.nih.gov/39996356/) reports fat and lean-mass change with tirzepatide. The [systematic body-composition review](https://pubmed.ncbi.nlm.nih.gov/41996180/) examines incretin therapies and the physical-function gap. For semaglutide, [STEP 1](https://pubmed.ncbi.nlm.nih.gov/33567185/) supplies the total-weight comparison and [STEP 5](https://pubmed.ncbi.nlm.nih.gov/36216945/) extends the observation over two years.

## Semaglutide heart studies

The [STEP-HFpEF trial](https://pubmed.ncbi.nlm.nih.gov/37622681/) concerns symptoms and physical limitations in obesity-related heart failure with preserved ejection fraction. [SELECT](https://pubmed.ncbi.nlm.nih.gov/37952131/) concerns major cardiovascular events in adults with cardiovascular disease and overweight or obesity without diabetes.

## Withdrawal and tolerability studies

The [SURMOUNT-4 trial](https://pubmed.ncbi.nlm.nih.gov/38078870/) and its [cardiometabolic analysis](https://pubmed.ncbi.nlm.nih.gov/41284285/) follow tirzepatide withdrawal. [SURMOUNT-1](https://pubmed.ncbi.nlm.nih.gov/35658024/) supplies the tirzepatide gastrointestinal finding. The semaglutide [safety review](https://pubmed.ncbi.nlm.nih.gov/34305810/) and [SUSTAIN-6](https://pubmed.ncbi.nlm.nih.gov/27633186/) supply the gallbladder, rare-event and eye findings discussed here.

## References

[1] Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. https://pubmed.ncbi.nlm.nih.gov/39996356/
[2] Once-Weekly Semaglutide in Adults with Overweight or Obesity https://pubmed.ncbi.nlm.nih.gov/33567185/
[3] Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/37622681/
[4] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes https://pubmed.ncbi.nlm.nih.gov/37952131/
[5] Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. https://pubmed.ncbi.nlm.nih.gov/41284285/
[6] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/38078870/
[7] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial https://pubmed.ncbi.nlm.nih.gov/36216945/
[8] Tirzepatide Once Weekly for the Treatment of Obesity https://pubmed.ncbi.nlm.nih.gov/35658024/
[9] Safety of Semaglutide https://pubmed.ncbi.nlm.nih.gov/34305810/
[10] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27633186/
[11] Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review. https://pubmed.ncbi.nlm.nih.gov/41996180/

---

At TX Medical Weight Loss Center I consider what weight loss contains through published research, in an editorial collection that offers neither healthcare business services nor medical advice.